There were more patients with preoperative CEA ≥ 30ng/ml (53.1% vs 27.7%; p = 0.000), primary tumor lymphovascular invasion (LVI) (55.4% vs 25.0%; p = 0.000), lymph node metastases (40.1% vs 20.5%; p = 0.000), initially unresectable disease (41.7% vs 24.3%; p = 0.004), the number of metastases ≥ 4 (70.2% vs 26.3%; p = 0.000), bilobar metastases (63.2% vs 27.4%; p = 0.000), R1 resection (52.1% vs 27.2%; p = 0.000) and major complications (54.2% vs 32.0%; p = 0.03) who developed early recurrence. Here, CEACAM5 is linked to metastatic malignant neoplasm in the lymph nodes.